ALK and non-small cell lung carcinoma: The identification of EML4-ALK as an oncogenic driver in NSCLC in the clinical development of crizotinib and the observation of promising clinical responses in patients with NSCLC harboring ALK translocations accelerated its clinical development in ALK-positive NSCLC (15).